vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and AVIENT CORP (AVNT). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $760.6M, roughly 1.2× AVIENT CORP). AVIENT CORP runs the higher net margin — 2.2% vs 0.7%, a 1.5% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 1.9%). AVIENT CORP produced more free cash flow last quarter ($125.4M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -4.2%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Avient Corporation is a global materials solutions company headquartered in Avon Lake, Ohio, United States, employing approximately 9,000 people worldwide. Its products include colorants, advanced composites, functional additives and engineered materials.
ASTH vs AVNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $760.6M |
| Net Profit | $6.6M | $16.9M |
| Gross Margin | — | 30.2% |
| Operating Margin | 1.9% | 5.2% |
| Net Margin | 0.7% | 2.2% |
| Revenue YoY | 42.9% | 1.9% |
| Net Profit YoY | 184.4% | -65.0% |
| EPS (diluted) | $0.12 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $760.6M | ||
| Q3 25 | $956.0M | $806.5M | ||
| Q2 25 | $654.8M | $866.5M | ||
| Q1 25 | $620.4M | $826.6M | ||
| Q4 24 | $665.2M | $746.5M | ||
| Q3 24 | $478.7M | $815.2M | ||
| Q2 24 | $486.3M | $849.7M | ||
| Q1 24 | $404.4M | $829.0M |
| Q4 25 | $6.6M | $16.9M | ||
| Q3 25 | $373.0K | $32.6M | ||
| Q2 25 | $9.4M | $52.6M | ||
| Q1 25 | $6.7M | $-20.2M | ||
| Q4 24 | $-7.8M | $48.3M | ||
| Q3 24 | $16.1M | $38.2M | ||
| Q2 24 | $19.2M | $33.6M | ||
| Q1 24 | $14.8M | $49.4M |
| Q4 25 | — | 30.2% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | — | 32.1% | ||
| Q2 24 | — | 30.3% | ||
| Q1 24 | — | 33.6% |
| Q4 25 | 1.9% | 5.2% | ||
| Q3 25 | 2.0% | 8.3% | ||
| Q2 25 | 3.1% | 11.1% | ||
| Q1 25 | 3.3% | 0.1% | ||
| Q4 24 | 0.1% | 11.5% | ||
| Q3 24 | 5.9% | 9.5% | ||
| Q2 24 | 6.2% | 8.5% | ||
| Q1 24 | 7.5% | 11.3% |
| Q4 25 | 0.7% | 2.2% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 1.4% | 6.1% | ||
| Q1 25 | 1.1% | -2.4% | ||
| Q4 24 | -1.2% | 6.5% | ||
| Q3 24 | 3.4% | 4.7% | ||
| Q2 24 | 3.9% | 4.0% | ||
| Q1 24 | 3.7% | 6.0% |
| Q4 25 | $0.12 | $0.18 | ||
| Q3 25 | $0.01 | $0.36 | ||
| Q2 25 | $0.19 | $0.57 | ||
| Q1 25 | $0.14 | $-0.22 | ||
| Q4 24 | $-0.14 | $0.53 | ||
| Q3 24 | $0.33 | $0.41 | ||
| Q2 24 | $0.40 | $0.36 | ||
| Q1 24 | $0.31 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | — |
| Total DebtLower is stronger | — | $1.9B |
| Stockholders' EquityBook value | $779.3M | $2.4B |
| Total Assets | $2.2B | $6.0B |
| Debt / EquityLower = less leverage | — | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | — | ||
| Q2 25 | $342.1M | — | ||
| Q1 25 | $260.9M | — | ||
| Q4 24 | $290.8M | — | ||
| Q3 24 | $350.3M | — | ||
| Q2 24 | $327.7M | — | ||
| Q1 24 | $337.3M | — |
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.1B |
| Q4 25 | $779.3M | $2.4B | ||
| Q3 25 | $775.5M | $2.4B | ||
| Q2 25 | $765.5M | $2.4B | ||
| Q1 25 | $745.4M | $2.3B | ||
| Q4 24 | $712.7M | $2.3B | ||
| Q3 24 | $704.6M | $2.4B | ||
| Q2 24 | $678.9M | $2.3B | ||
| Q1 24 | $653.5M | $2.3B |
| Q4 25 | $2.2B | $6.0B | ||
| Q3 25 | $2.2B | $6.1B | ||
| Q2 25 | $1.4B | $6.1B | ||
| Q1 25 | $1.3B | $5.8B | ||
| Q4 24 | $1.4B | $5.8B | ||
| Q3 24 | $1.3B | $6.0B | ||
| Q2 24 | $1.3B | $5.9B | ||
| Q1 24 | $1.2B | $5.9B |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 0.89× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.90× | ||
| Q1 24 | — | 0.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $167.8M |
| Free Cash FlowOCF − Capex | $-6.0M | $125.4M |
| FCF MarginFCF / Revenue | -0.6% | 16.5% |
| Capex IntensityCapex / Revenue | 0.3% | 5.6% |
| Cash ConversionOCF / Net Profit | -0.44× | 9.93× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $195.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $167.8M | ||
| Q3 25 | $10.0M | $72.1M | ||
| Q2 25 | $90.9M | $112.8M | ||
| Q1 25 | $16.6M | $-51.1M | ||
| Q4 24 | $-10.9M | $122.6M | ||
| Q3 24 | $34.0M | $71.1M | ||
| Q2 24 | $23.2M | $105.9M | ||
| Q1 24 | $6.0M | $-42.8M |
| Q4 25 | $-6.0M | $125.4M | ||
| Q3 25 | $7.4M | $47.4M | ||
| Q2 25 | $89.5M | $85.8M | ||
| Q1 25 | $13.6M | $-63.6M | ||
| Q4 24 | $-13.5M | $81.5M | ||
| Q3 24 | $31.7M | $46.1M | ||
| Q2 24 | $20.4M | $74.5M | ||
| Q1 24 | $5.6M | $-67.2M |
| Q4 25 | -0.6% | 16.5% | ||
| Q3 25 | 0.8% | 5.9% | ||
| Q2 25 | 13.7% | 9.9% | ||
| Q1 25 | 2.2% | -7.7% | ||
| Q4 24 | -2.0% | 10.9% | ||
| Q3 24 | 6.6% | 5.7% | ||
| Q2 24 | 4.2% | 8.8% | ||
| Q1 24 | 1.4% | -8.1% |
| Q4 25 | 0.3% | 5.6% | ||
| Q3 25 | 0.3% | 3.1% | ||
| Q2 25 | 0.2% | 3.1% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 0.4% | 5.5% | ||
| Q3 24 | 0.5% | 3.1% | ||
| Q2 24 | 0.6% | 3.7% | ||
| Q1 24 | 0.1% | 2.9% |
| Q4 25 | -0.44× | 9.93× | ||
| Q3 25 | 26.69× | 2.21× | ||
| Q2 25 | 9.65× | 2.14× | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | 2.54× | ||
| Q3 24 | 2.11× | 1.86× | ||
| Q2 24 | 1.21× | 3.15× | ||
| Q1 24 | 0.40× | -0.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
AVNT
| Color Additives And Inks | $466.0M | 61% |
| Specialty Engineered Materials | $295.5M | 39% |
